Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hypertension Age: Adult Condition: Oral |
Dose: Conventional tablet – Initially 100 mg/day Frequency: once daily or in 2 divided doses Note: May increase weekly to 400 mg/day depending on response. Maintenance: 100-200 mg/day. Hepatic impairment: Reduce dose. |
|
Indication: Hypertension Age: Adult Condition: Oral |
Dose: Extended-release tablet – Initially 25-100 mg Frequency: once daily Note: Hepatic impairment: Reduce dose. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hypertension Age: 1-17 years |
Dose: Conventional tablet – 1-2 mg/kg/day Frequency: divided twice daily Note: by mouth (oral); not to exceed 6 mg/kg/day or 200 mg/day |
|
Indication: Hypertension Age: greater than 6 years |
Dose: Extended-release tablet – 1 mg/kg Frequency: once daily Note: by mouth (oral); not to exceed 50 mg/day initially; adjusted on basis of patient response; not to exceed 2 mg/kg/day or less than 200 mg/day |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: dosage - No dosage adjustment needed Note: Renal impairment: No dosage adjustment needed. |
Administration
- May be taken with or without food
- Take at same times each day
Side Effect
- Dizziness (10%)
- Headache (10%)
- Tiredness (10%)
- Depression (5%)
- Diarrhea (5%)
- Pruritus (5%)
- Bradycardia (9%)
- Rash (5%)
- Dyspnea (1-3%)
- Cold extremities (1%)
- Constipation (1%)
- Dyspepsia (1%)
- Heart failure (1%)
- Hypotension (1%)
- Nausea (1%)
- Flatulence (1%)
- Heartburn (1%)
- Xerostomia (1%)
- Wheezing (1%)
- Bronchospasm (1%)
- Decreased exercise tolerance
- Raynaud phenomenon
- Increased triglyceride levels and insulin resistance
- decreased high-density lipoprotein (HDL) levels
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Reserpine, MAOIs (Phenelzine, Tranylcypromine, Selegiline, Moclobemide)
|
Additive effect with catecholamine-depleting drugs
|
|
Sympathomimetics (Ephedrine, Pseudoephedrine, Phenylephrine)
|
May antagonise β1-adrenergic stimulating effects
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
2nd Degree AV Block
|
Risk of complete heart block
|
|
3rd Degree AV Block
|
Risk of complete heart block
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store in a cool, dry place protected from light. Keep out of reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.